June National Health Observances: Alzheimer’s Disease, Safety, HIV, and More

Each month we feature select National Health Observances (NHOs) that highlight important health issues affecting people across the nation. In June we’re raising awareness about Alzheimer’s disease and brain health, safety, HIV testing and sickle cell disease.

 

Related Articles

5 Essential Frameworks for Preventing Violent Child Death

The U.S. has a violent child death problem. Developing strategies to prevent violent child deaths death from firearms and traffic crashes is a demanding task that requires consideration of numerous upstream, interrelated, and tangential issues. To help safety advocates develop strategies to prevent violent child death, we compiled five frameworks to help: Understand and explain …
The post 5 Essential Frameworks for Preventing Violent Child Death appeared first on Salud America.

The Critical State of Alzheimer’s and Dementia in Latinos

Alzheimer’s disease is a condition that impairs brain function and, over time, can cause memory, cognitive, and behavioral issues and eventually lead to death. The condition greatly impacts the health of the aging — especially Latinos. 14% of the American Latino population older than 65 are living with Alzheimer’s, compared with 10% of the White …
The post The Critical State of Alzheimer’s and Dementia in Latinos appeared first on Salud America.

Recognizing National Latinx Aids Awareness Day

October 15, 2022 is National Latinx Aids Awareness Day (NLAAD). This observance calls for raising awareness on the impact of HIV on Hispanic/Latino/Latinx communities and eliminating stigma. NLAAD, first created by the by the Hispanic Federation and the Latino Commission on AIDS in 2003, is a good opportunity to feature the CDC’s Let’s Stop HIV Together …
The post Recognizing National Latinx Aids Awareness Day appeared first on Salud America.

FDA Approves New Drug for Alzheimer’s, But Scientists Divided Over Decision

The U.S. Food and Drug Administration approved a new drug called Aduhelm (aducanumab) to treat Alzheimer’s disease, the most common form of dementia. Many are applauding the drug and are encouraged by the scientific progress in a field that has long had limited treatment options. Alzheimer’s affects over 6.2 million people in the U.S., with …
The post FDA Approves New Drug for Alzheimer’s, But Scientists Divided Over Decision appeared first on Salud America.

Responses